
Solventum Corporation (SOLV) Stock Forecast & Price Target
Solventum Corporation (SOLV) Analyst Ratings
Bulls say
Solventum is a promising healthcare company with strong financials and potential for growth due to its innovative solutions and focus on material science and digital capabilities. The recent spinoff from 3M has allowed Solventum to streamline operations and focus on growth in key segments. Furthermore, they have a steady cadence of M&A and potential for divestiture in non-core product areas, providing additional flexibility for growth. With a solid Q1 performance and a strong outlook for 2026, we believe SOLV will continue to progress towards their 2028 financial targets and maintain our Buy rating and raised price target of $93.
Bears say
Solventum is facing a challenging healthcare market with slowing organic growth and increased competition. Furthermore, the company's dependence on the United States for the majority of its revenue exposes it to potential regulatory risks and changes in healthcare spending. Additionally, delays in the spin-off or execution of portfolio optimization could weigh on the company's growth prospects. The company's valuation also remains questionable, as it trades at a lower P/E multiple compared to peers with higher growth rates and could face downward pressure in an already competitive market.
This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.
Solventum Corporation (SOLV) Analyst Forecast & Price Prediction
Start investing in Solventum Corporation (SOLV)
Order type
Buy in
Order amount
Est. shares
0 shares